Skip to main content
Premium Trial:

Request an Annual Quote

Danish Partners Embark on $6.8M Personalized Cancer Diagnostics Project

NEW YORK (GenomeWeb News) – Partners in Denmark have joined to embark on a €5.2 million ($6.8 million) personalized cancer diagnostic project.

The project aims to develop a platform for precision medicine using gene expression analysis so that individual cancer patients can receive treatments that have been tailored specifically for them.

The members of the project are Vejle Hospital, the Technical University of Denmark, Exiqon, and Intomics. The five-year project will focus on colorectal cancer, and the Danish National Advanced Technology Foundation has provided €3.0 million toward it.

The hospital has conducted research into colorectal cancer, it said, and will contribute research with "well-defined patient groups." Exiqon will provide its expertise in and technology for measuring genetic biomarkers, while Intomics and the university provides their bioinformatics expertise in handling large amounts of complex genetic data.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.